Современное состояние проблемы диагностики и лечения диффузно растущих глиом ствола мозга у детей и подростков

Современное состояние проблемы диагностики и лечения диффузно растущих глиом ствола мозга у детей и подростков

Автор: Регентова О.С., Щербенко О.И.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 1 т.19, 2019 года.

Бесплатный доступ

Диффузно растущие опухоли ствола мозга относятся к числу наиболее тяжелых и, на сегодняшний день, практически неизлечимых заболеваний. В настоящее время их диагностика главным образом основывается на данных клинико-рентгенологического исследования. Лучевая терапия остается единственным реальным средством временной стабилизации роста опухоли и увеличения сроков жизни. Длительность достигаемого при этом эффекта зависит от степени агрессивности опухоли. При возобновлении роста опухоли повторная лучевая терапия в большинстве случаев позволяет улучшить качество жизни больного и увеличить ее продолжительность, но ее стратегия (показания, дозирование, сопроводительная терапия) пока не разработана, что обусловливает редкость ее использования. Применение существующих химиопрепаратов не внесло существенных изменений в результаты лучевой терапии. Надежда на повышение эффективности лечения связана с начатым в последнее время изучением молекулярно-генетических особенностей опухоли, что создаст основу для создания методик таргетной терапии.

Еще

Дети, ствол мозга, опухоли, лучевая терапия, химиотерапия, качество жизни, молекулярно-генетическе особенности, таргетная терапия

Короткий адрес: https://sciup.org/149132092

IDR: 149132092

Список литературы Современное состояние проблемы диагностики и лечения диффузно растущих глиом ствола мозга у детей и подростков

  • Синельников Р.Д., Синельников Я.Р., Синельников А.Я. Атлас анатомии человека. Том 4.
  • Щербенко О.И., Пархоменко Р.А., Зелинская Н.И.,Антоненко Ф.Ф. Эффективность повторной лучевой терапии при продолженном росте диффузно растущих опухолей ствола мозга у детей. Российский журнал детской гематологии и онкологии. 2014. № 2. С. 79-80.
  • Adamczyk L.A., Williams H., Frankow A. et al. Current Understanding of Circulating Tumor Cells -Potential Value in Malignancies of the Central Nervous System. Front Neurol. 2015. V.6 Р. 174. DOI: 10.3389/fneur.2015.00174
  • Akers J.C., Hua W., Li H. et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017. V. 8. No. 40. Р. 68769-68779. DOI: 10.18632/oncotarget.18332
  • Akers J.C., Ramakrishnan V., Kim R. et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol. 2015. V. 123. No. 2. Р. 205-216. DOI: 10.1007/s11060-015-1784-3
  • Akers J.C., Ramakrishnan V., Nolan J.P. et al. Comparative analysis of technologies for quantifying extracellular vesicles (EVs) in clinical cerebrospinal fluids (CSF). PLoS One. 2016. V. 11. No.2. e0149866.
  • DOI: 10.1371/journal.pone.0149866
  • Akers J.C., Ramakrishnan V., Yang I. et al. Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark. 2016. V. 17. No. 2. Р. 125-132.
  • DOI: 10.3233/CBM-160609
  • Alix-Panabières C., Schwarzenbach H., Pantel K., et al. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012. V. 63. Р. 199-215.
  • DOI: 10.1146/annurev-med-062310-094219
  • Bailey S., Howman A., Wheatley K. et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy-results of a United Kingdom phase II trial (CNS 2007 04).Eur J Cancer. 2013. V. 49. No. 18. Р.3856-3862.
  • DOI: 10.1016/j.ejca.2013.08.006
  • Ballester L.Y., Wang Z., Shandilya S. et al. Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas. Am J Surg Pathol. 2013. V.37.No. 9. P. 1357-1364.
  • DOI: 10.1097/PAS.0b013e318294e817
  • Bender S., Tang Y., Lindroth A.M. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27 M mutant pediatric high-grade gliomas. Cancer Cell. 2013. V. 24. No. 5. Р. 660-672.
  • DOI: 10.1016/j.ccr.2013.10.006
  • Bradley K.A., Zhou T., McNall-Knapp R.Y. et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study. Int J Radiat Oncol Biol Phys. 2013. V. 85. No. 1. P. 55-60.
  • DOI: 10.1016/j.ijrobp.2012.09.004
  • Buczkowicz P., Bartels U., Bouffet E. et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014. V. No. 128. Р. 573-581.
  • Buczkowicz P., Hoeman C., Gan H. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014. V. 46. No. 5. Р. 451-456.
  • Chan K.M, Fang D.,Gan H. et al. The histone H3.3K27 M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013. V. 27. No. 9. Р. 985-
  • Chassot A., Canale S. Varlet P. et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012. V. 106. No. 2. Р. 399-407.
  • DOI: 10.1007/s11060-011-0681-7
  • Chen W.W., Balaj L., Liau L.M. et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013. V. 2. e109.
  • DOI: 10.1038/mtna.2013.28
  • Chen J., Huan W., Zuo H. et al. Alu methylation serves as a biomarker for non-invasive diagnosis of glioma. Oncotarget. 2016. V. 7. No. 18. Р. 26099-26106.
  • DOI: 10.18632/oncotarget.8318
  • Cheng C., Omura-Minamisawa M., Kang Y. et al. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci. 2009. V. 100. No. 2. Р. 303-309.
  • DOI: 10.1111/j.1349-7006.2008.01021.x
  • Chiang K.L., Chang K.P. Lee Y.Y. et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst. 2010. V. 26. No. 8. Р. 1035-1041.
  • DOI: 10.1007/s00381-010-1106-1
  • Cohen K.J., Heideman R.L., Zhou T. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro-Oncol. 2011. V. 13. No. 4. Р. 410-416.
  • DOI: 10.1093/neuonc/noq205
  • Cooney T., Lane A., Bartels U. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro-Oncol. 2017. V. 19. No. 9. Р. 1279-1280.
  • DOI: 10.1093/neuonc/nox107
  • Dawson S.J., Tsui D.W., Murtaza M. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England Journal of Medicine (NEJM). 2013. No. 368. Р. 1199-1209.
  • DOI: 10.1056/NEJMoa1213261
  • Diehl F., Schmidt K., Choti M.A. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008. V. 14. No. 9. Р. 985-990.
  • DOI: 10.1038/nm.1789
  • Ferreira M.M., Ramani V.C., Jeffrey S.S. Circulating tumor cell technologies. Mol Oncol. 2016. V. 10. No. 3. Р. 374-394.
  • DOI: 10.3389/fneur.2015.00174
  • Figueroa J.M., Skog J., Akers J. et al. Detection of wt EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncol. 2017. V. 19. No. 11. Р. 1494-1502.
  • DOI: 10.1093/neuonc/nox085
  • Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer -A survey. Biochim Biophys Acta. 2007. V. 1775. No. 1. Р. 181-232.
  • Fontanilla H.P., Pinnix C.C., Ketonen L.M. et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012 Feb. V. 35. No. 1. Р. 51-57.
  • DOI: 10.1097/COC.0b013e318201a2b7uro
  • Fontebasso A.M., Papillon-Cavanagh S., Schwartzentruber J. et al. Recurrent somatic mutations in ACVR1 in pediatric midline highgrade astrocytoma. Nat Genet. 2014. No. 46. Р. 462-466.
  • Freese C., Takiar V., Fouladi M. et al. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol. 2017. V. 7. No. 2. Р. 86-92.
  • DOI: 10.1016/j.prro.2016.11.005
  • Fritz J.V., Heintz-Buschart A., Ghosal A. et al. Sources and functions of extracellular small RNAs in human circulation. Annu Rev Nutr. 2016. No. 36. Р. 301-336.
  • DOI: 10.1146/annurev-nutr-071715-050711
  • Gao F., Cui Y. Jiang H. et al. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016. V. 7. No. 44. Р. 71330-71340.
  • DOI: 10.18632/oncotarget.11114
  • Giussani C., Poliakov A., Ferri R.T. et al. DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. Neuroimage. 2010. No. 52. Р. 217-223.
  • Gokce-Samar Z., Beuriat P.A., Faure-Conter C. et al. Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst. 2016. V. 32. No. 8. Р. 1415-1423.
  • DOI: 10.1007/s00381-016-3153-8
  • Green A.L., Kieran M.W. et al. Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. Curr Oncol Rep. 2015. V. 17. No. 3. Р. 436.
  • Grimm S.A., Chamberlain M.C. Brainstem glioma: a review. Curr Neurol Neurosci Rep. 2013. V. 13. No. 5. Р. 346.
  • Guillamo J.S., Doz F., Delattre J.Y. Brain stem gliomas. Current opinion in neurology. 2001. V.14. № 6. Р. 711-715.
  • Gururangan S., Chi S.N., Young Poussaint T. et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010. V. 28. No. 18. Р. 3069-3075.
  • DOI: 10.1200/JCO.2009.26.8789
  • Haas-Kogan D.A., Banerjee A., Poussaint T.Y. et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro-Oncol. 2011. V. 13. No. 3. Р. 298-306.
  • DOI: 10.1093/neuonc/noq202
  • Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. The Lancet Oncology. 2006. V. 7. No. 3. Р. 241-248.
  • Hu X., Fang Y., Hui X. et al. Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev. 2016. V. 27. No. 6. CD010439.
  • DOI: 10.1002/14651858.CD010439.pub2
  • Huang T.Y., Piunti A., Lulla R.R. et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017. V. 5. No. 1. Р. 28.
  • DOI: 10.1186/s40478-017-0436-6
  • Hummel T.R., Salloum R., Drissi R. et al. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neuro-Oncol. 2016. V. 127. No. 1. Р. 53-61.
  • DOI: 10.1007/s11060-015-2008-6
  • Isa O.N., Reyes C.M., Russo N.M. Radiation therapy in the treatment of brain-stem tumors in children. Rev Chil Pediatr. 2014. V. 85. No. 1. Р. 40-45.
  • DOI: 10.4067/S0370-41062014000100005
  • Janssens G.O., Gandola L., Bolle S. et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017. No. 73. Р. 38-47.
  • DOI: 10.1016/j.ejca.2016.12.007
  • Janssens G.O., Jansen M.H., Lauwers S.J. et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys. 2013. V. 85. No. 2. Р. 315-320.
  • DOI: 10.1016/j.ijrobp.2012.04.006
  • Kim C.Y., Kim S.K., Phi J.H. et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol. 2010. V. 100. No. 2. Р. 193-198.
  • DOI: 10.1007/s11060-010-0157-1
  • La Madrid A.М., Santa-María V., Martinez С. et al. Second re-irradiation for DIPG progression, re-considering "old strategies" with new approaches. Childs Nerv Syst. 2017. V. 33. No. 5. Р. 849-852.
  • DOI: 10.1007/s00381-017-3352-y
  • Lassaletta A., Strother D., Laperriere N. et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatr Blood Cancer. 2018. V. 65. No. 6. e26988.
  • DOI: 10.1002/pbc.26988
  • Lee A., Youssef I., Osborn V.W. et al. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. J Clin Neurosci. 2018. V. 51. No. 5. Р. 85-90.
  • DOI: 10.1016/j.jocn.2018.02.009
  • Li M., Chen W.D., Papadopoulos N. et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009. V. 27. No. 9. Р. 858-863.
  • DOI: 10.1038/nbt.1559
  • Hoffman L.M., Veldhuijzen van Zanten SEM, Colditz N. et al. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J ClinOncol. 2018. V. 36. No. 19. Р. 1963-1972.
  • Lo Y.M., Leung S.F., Chan L.Y. et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000. V. 60. No. 9. Р. 2351-2355.
  • Lobel U., Sedlacik J., Reddick W.E. et al. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2011. V.32. No. 2. Р. 315-322.
  • Lobel U., Sedlacik J., Sabin N.D. et al. Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. Neuroradiology. 2010. V. 52. No. 12. Р. 1167-1177.
  • Lohr J.G., Adalsteinsson V.A., Cibulskis K. et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014. V. 32. No. 5. Р. 479-484.
  • DOI: 10.1038/nbt.2892
  • Macarthur K.M., Kao G.D., Chandrasekaran S. et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014. No. 74. Р. 2152-2159.
  • DOI: 10.1158/0008-5472.CAN-13-0813
  • Macy M.E., Kieran M.W., Chi S.N. et al. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: APediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017. V. 64. No. 11. Р. 11.
  • DOI: 10.1002/pbc.26621
  • Manda S.V., Kataria Y., Tatireddy B.R. et al. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. J Neurosurg. 2017. V. 128. No.4 P. 1091-1101.
  • DOI: 10.3171/2016.11.JNS161187
  • Michalski A., Bouffet E., Taylor R.E. et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neuro-Oncol. 2010. V. 100. No. 1. Р. 81-88.
  • DOI: 10.1007/s11060-010-0141-9
  • Mu L., Xu W., Li Q. et al. IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours. Journal of Cancer. 2017. V. 8. No. 14. Р. 2704-2712.
  • DOI: 10.7150/jca.20665
  • Muller C., Holtschmidt J., Auer M. et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014. V. 6. No. 247. Р. 247-301.
  • DOI: 10.1126/scitranslmed.3009095
  • Müller K., Schlamann A., Seidel C. et al. Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment. Strahlenther Onkol. 2013. V. 189. No. 8. Р. 693-696.
  • DOI: 10.1007/s00066-013-0370-x
  • Negretti L., BouchirebK., Levy-Piedbois C. et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neuro-Oncol. 2011. V. 104. No. 3. Р. 773-777.
  • DOI: 10.1007/s11060-011-0542-4
  • Ostrom Q.T., Gittleman H., Liao P. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncol. 2014. No.16.Suppl 4: iv1-63.
  • Oxnard G.R., Paweletz C.P.,Kuang Y. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. V. 20. No. 6. Р. 1698-1705.
  • DOI: 10.1158/1078-0432
  • Perez-Gomez J.L., Rodriguez-Alvarez C.A., Marhx-Bracho A., Rueda-Franco F. Stereotactic biopsy for brainstem tumors in pediatric patients. Childs Nerv Syst. 2010. V. 26. No. 1.Р. 29-34.
  • Porkholm M., Valanne L., Lönnqvist T. et al. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2014. V. 61. No. 9. Р. 1603-1609.
  • DOI: 10.1002/pbc.25045
  • Pratt E.D., Huang C.,Hawkins B.G. et al. Rare cell capture in micro-fluidic devices. Chem Eng Sci. 2011. V. 66. No. 7. Р. 1508-1522.
  • DOI: 10.1016/j.ces.2010.09.012
  • Rajshekhar V., Moorthy R.K. Status of stereotactic biopsy in children with brain stem masses: insights from a series of 106 patients. Stereotact Funct Neurosurg. 2010. V. 88. No. 6. Р. 360-366.
  • DOI: 10.1159/000319044
  • Rizzo D., Scalzone M., Ruggiero A. et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother. 2015. V. 27. No. 2. Р. 106-110.
  • DOI: 10.1179/1973947814Y.0000000228
  • Robison N.J., Kieran M.W. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol. 2014. V. 119. No. 1. No. 1. Р. 7-15.
  • Roujeau T., Di Rocco F., Dufour C. et al. Shall we treat hydrocephalus associated to brain stem glioma in children? Childs Nerv Syst. 2011. V. 27. No. 10. Р. 1735-1739.
  • DOI: 10.1007/s00381-011-1538-2
  • Roujeau T, Machado G., Garnett M.R. et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007. V. 107 (1 Suppl). Р. 1-4.
  • Santiago-Dieppa D.R., Gonda D.D., Cheung V.J. et al. Extracellular Vesicles as a Platform for Glioma Therapeutic Development. Prog Neurol Surg. 2018. V. 32. Р. 172-179.
  • DOI: 10.1159/000469689
  • Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014. V. 2014. No. 1. Р. 244-249.
  • DOI: 10.1182/asheducation-2014.1.244
  • Schwartzentrnber J., Korshunov A., Liu X.Y. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012. V. 482. No. 7384. Р. 226-231.
  • Sethi R., Allen J., Donahue B. et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol. 2011. V. 102. No. 1. Р. 121-127.
  • Shao H., Chung J.,balaj L. et al. Protein typing of circulating micro-vesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012. V. 18. No. 12. Р. 1835-1840.
  • DOI: 10.1038/nm.2994
  • Skog J., Wurdinger T., van Rijn S. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008. V. 10. No.12 Р. 1470-1476.
  • DOI: 10.1038/ncb1800
  • Sorensen B.S., Wu L.,Wei W. et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung Cancer during treatment with erlotinib. Cancer. 2014. V. 120. No.24 Р. 3896-3901.
  • DOI: 10.1002/cncr.28964
  • Steffen-Smith E.A., Shih J.H., Hipp S.J. et al. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neuro-Oncol. 2011. V. 105. No. 2. Р. 365-373.
  • DOI: 10.1007/s11060-011-0601-x
  • Sullivan J.P., Nahed B.V., Madden M.W. et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014. V. 4. No. 11. Р. 1299-1309.
  • Taylor K.R., Mackay A., Truffaux N. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014. V. 46. No. 5.Р. 457-461.
  • Tisnado J., Young R., Peck K.K., Hague S. Conventional and Advanced Imaging of Diffuse Intrinsic Pontine Glioma. J Child Neurol. 2016. V. 31. No. 12. Р. 1386-1393.
  • DOI: 10.1177/0883073816634855
  • Veldhuijzen van Zanten S.E., Baugh J., Chaney B. et al. Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. J Neurooncol. 2017. V. 132. No. 2. Р. 255-266. -y.
  • DOI: 10.1007/s11060-016-2363
  • Veldhuijzen van Zanten S.E., Cruz O., Kaspers G.J. et al. State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. J Neurooncol. 2016. V. 128. No. 3. Р. 387-394.
  • DOI: 10.1007/s11060-016-2141-x
  • Veldhuijzen van Zanten S.E.M., El-Khouly F.E., Jansen M.H.A. et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017. V. 135. No. 2. Р. 307-315.
  • DOI: 10.1007/s11060-017-2575-9
  • Wang Y., Springer S., Zhang M. et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015. V.112 No. 31. Р.9704-9709.
  • DOI: 10.1073/pnas.1511694112
  • Warren K.E. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2012. No. 2. Р.205
  • DOI: 10.3389/fonc.2012.00205
  • Wells E.M., Packer R.J. Pediatric brain tumors. Continuum (MinneapMinn). 2015. V. 21 (2 Neuro-oncology). Р. 373-396.
  • Wolff J.E., Rytting M.E., Vats P.E. et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012. V. 106. No. 2. Р. 391-397.
  • DOI: 10.1007/s11060-011-0677-3
  • Wu G., Broniscer A., McEachron T.A. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012. V. 44. No. 3. Р. 251-253.
  • DOI: 10.1038/ng.1102
  • Wu G., Diaz A.K., Paugh B.S. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014. V. 46. No. 5.Р. 444-450.
  • Zaghloul M.S., Eldebawy E.,Ahmed S. et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol. 2014. V. 111. No. 1. Р. 35-40.
  • DOI: 10.1016/j.radonc.2014.01.013
  • Zaky W., Wellner M.,Brown R.J. et al. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab. Pediatr Hematol Oncol. 2013. V. 30. No. 7. Р. 623-632.
  • DOI: 10.3109/08880018.2013.829895
Еще
Статья научная
SciUp 2024 © 2024 ©